N6-Cyclopentyladenosine (Standard)

[1]. Klotz KN, et al. Adenosine receptors and their ligands. Naunyn Schmiedebergs Arch Pharmacol. 2000 Nov;362(4-5):382-91. [Content Brief]

[2]. Soliño M, et al. Adenosine A1 receptor: A neuroprotective target in light induced retinal degeneration. PLoS One. 2018 Jun 18;13(6):e0198838. [Content Brief]

[3]. Mlejnek P, et al. Apoptosis induced by N6-substituted derivatives of adenosine is related to intracellular accumulation of corresponding mononucleotides in HL-60 cells. Toxicol In Vitro. 2005 Oct;19(7):985-90. [Content Brief]

[4]. Pospísil M, et al. N6-cyclopentyladenosine inhibits proliferation of murine haematopoietic progenitor cells in vivo. Eur J Pharmacol. 2005 Jan 10;507(1-3):1-6. [Content Brief]

[5]. Schwierin B, et al. Effects of N6-cyclopentyladenosine and caffeine on sleep regulation in the rat. Eur J Pharmacol. 1996 Apr 11;300(3):163-71. [Content Brief]

[6]. Normile HJ, et al. N6-cyclopentyladenosine impairs passive avoidance retention by selective action at A1 receptors. Brain Res Bull. 1991 Jul;27(1):101-4. [Content Brief]

[7]. Mathôt RA, et al. Pharmacokinetic-pharmacodynamic relationship of the cardiovascular effects of adenosine A1 receptor agonist N6-cyclopentyladenosine in the rat. J Pharmacol Exp Ther. 1994 Feb;268(2):616-24. [Content Brief]

[8]. Mathôt RA, et al. Deoxyribose analogues of N6-cyclopentyladenosine (CPA): partial agonists at the adenosine A1 receptor in vivo. Br J Pharmacol. 1995 Oct;116(3):1957-64. [Content Brief]

[9]. Jaishree J, et al. Individual and combined effects of N6-cyclopentyladenosine, flunarizine and diazepam on aminophylline-induced recurrent generalized seizures in mice. Pol J Pharmacol. 2003 Jul-Aug;55(4):559-64. [Content Brief]